USP development with CHO cells
At a glance
CDR-Life is a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based T cell engager technology. The collaboration between the competence center for Biochemical Engineering and Cell Cultivation Technique at ZHAW and CDR-Life has been established for the joint upstream process development and optimization for CDR-Life’s CDR404 program. The objective is the design of an efficient, robust, and scalable CHO-based bioprocess setting the foundation for future clinical manufacturing campaigns.